DeepHealth Brain (Neuro Suite)
Assess and monitor neurodegenerative changes with quantitative data
Software · Cloud SaaSCompany source
Company profile
About Quantib
DeepHealth, Inc. is a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT). Originally founded as Quantib in 2013 as a spin-off of Erasmus MC in Rotterdam, The Netherlands, the company developed software enabling automatic analysis of medical imaging data, particularly MRI scans, to shorten and improve diagnostic accuracy. Using advanced machine learning techniques, Quantib's products could detect changes in tissue sooner than possible with the naked eye. After being acquired by RadNet in 2022 and rebranded as DeepHealth in 2023, the company has expanded its mission to push the boundaries of healthcare by leveraging advanced AI to enable operational efficiency, clinical confidence, and better delivery of care. DeepHealth's comprehensive portfolio includes Enterprise Imaging solutions (Diagnostic Suite, Operations Suite, and TechLive) and Population Health solutions targeting specific conditions including breast cancer, prostate cancer, lung nodules, neurodegenerative diseases, and thyroid conditions. The company serves healthcare providers worldwide with FDA-cleared and CE-marked AI software for radiologists, offering end-to-end solutions that streamline workflows, automate mundane tasks, and enhance diagnostic capabilities through quantitative imaging biomarkers and advanced analytics.
Company description Quantib official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Quantib?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Brain atrophy
- Breast cancer
- Lung nodules
- Neurodegenerative diseases
- Prostate cancer
- Thyroid conditions
- White matter hyperintensities
Who it serves
- Diagnostic imaging centers
- Health Systems
- Healthcare providers
- Radiology practices
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEurope · Global · United States
Company sourceOfficial website
Company milestones
Platform expansion
Acquired by RadNet in 2022, rebranded as DeepHealth in 2023, introduced new AI-powered radiology informatics and population screening solutions at ECR 2025 (February 2025)
Partnerships
Recorded partners
- Erasmus MC (founding institution)
- Fusion biopsy systems (compatibility mentioned)
- RadNet, Inc. (parent company)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
DeepHealth Lung (Chest Suite)
Enhanced nodule detection, reporting and patient management
Software · Cloud SaaSCompany source
DeepHealth Prostate (Prostate Suite)
Enhanced prostate cancer detection with fusion biopsy compatibility
Software · Cloud SaaSCompany source
Diagnostic Suite™
Unified diagnostic workspace with PACS functionality and AI-powered interpretation
Platform · Cloud SaaSCompany source
Operations Suite™
Unified workspace for smart operations with RIS functionality
Platform · Cloud SaaSCompany source
SmartMammo™ Breast Suite
Enhanced workflow and diagnostic accuracy in breast cancer detection
Software · Cloud SaaSCompany source
TechLive™
Multi-modality remote acquisition and collaboration platform
Platform · Cloud SaaSCompany source
Thyroid Suite
AI-powered, end-to-end solution for thyroid ultrasound imaging
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Computed tomography-based muscle and fat composition in a Dutch population: a cross-sectional study.Insights into imaging · Nov 22, 2025
Fat-Free Mass Derived From Bioimpedance Spectroscopy and Computed Tomography are in Good Agreement in Patients With Chronic Kidney Disease.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · Jan 1, 2025
Use of automated assessment for determining associations of low muscle mass and muscle loss with overall survival in patients with colorectal cancer - A validation study.Clinical nutrition ESPEN · Oct 1, 2024
Low muscle quality on a procedural computed tomography scan assessed with deep learning as a practical useful predictor of mortality in patients with severe aortic valve stenosis.Clinical nutrition ESPEN · Oct 1, 2024
The Development and External Validation of Artificial Intelligence-Driven MRI-Based Models to Improve Prediction of Lesion-Specific Extraprostatic Extension in Patients with Prostate Cancer.Cancers · Nov 17, 2023
Pediatric body composition based on automatic segmentation of computed tomography scans: a pilot study.Pediatric radiology · Nov 1, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Brain WMHK251527 · 510k · Sep 25, 2025
Quantib ProstateK230772 · 510k · Apr 17, 2023
Quantib ProstateK221106 · 510k · May 13, 2022
Quantib ProstateK202501 · 510k · Oct 11, 2020
Quantib NDK182564 · 510k · Dec 27, 2018
Quantib BrainK173939 · 510k · Mar 9, 2018
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Enhanced diagnostic accuracy
Breast cancer detection, prostate cancer detection
Workflow efficiency
Decreased clicks, automated mundane tasks
Earlier tissue change detection
Sooner than possible with naked eye
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Quantib
Recent articles published on Quantib's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.